Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Immunotherapy & Biofluid Biopsies 2016

AmirAli Talasaz's Biography



AmirAli Talasaz, Co-Founder, President & COO, Guardant Health

Dr. Amirali Talasaz, Ph.D. serves as the President and Chief Operating Officer of Guardant Health Inc. Mr. Talasaz is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he served as Senior Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on genetic analysis of circulating tumor cells for cancer management. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. Mr. Talasaz received his PhD in Electrical Engineering and MSc in Management Science from Stanford University.

AmirAli Talasaz Image

Circulating Tumor DNA in Advanced-Stage Cancer Patients – Somatic Genomic Landscape and its Clinical Utility

Tuesday, 1 November 2016 at 14:00

Add to Calendar ▼2016-11-01 14:00:002016-11-01 15:00:00Europe/LondonCirculating Tumor DNA in Advanced-Stage Cancer Patients – Somatic Genomic Landscape and its Clinical UtilityCancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) enables non-invasive profiling of solid tumor cancers. Liquid biopsy studies to date have been limited to modest-size cohorts and case studies. Somatic genomic profiles of over 15,000 patients with advanced-stage clinical cancer were determined by a highly accurate, deep-coverage ctDNA NGS test targeting 70 genes (Guardant360). Frequencies of somatic ctDNA alterations per gene were compared to those previously described in tissue sequencing projects (e.g., TCGA). Accuracy of ctDNA sequencing (PPV) was assessed by comparing with matched tissue tests. Different classes of clinical outcome benefits have been observed by liquid biopsy by detecting actionable mutations in cases with tissue QNS or actionable mutations emerging at time of progression or under-genotyped tumors.


Add to Calendar ▼2016-11-01 00:00:002016-11-02 00:00:00Europe/LondonCancer Immunotherapy and Biofluid Biopsies 2016Cancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com